Shanghai Zerun Biotechnology Co., Ltd ., Shanghai, China.
Hum Vaccin Immunother. 2020 Oct 2;16(10):2366-2369. doi: 10.1080/21645515.2020.1787064. Epub 2020 Sep 22.
The recent outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been characterized by the World Health Organization (WHO) as a controllable global pandemic. The spike (S) glycoprotein mediates binding to the angiotensin-converting enzyme 2 (ACE2) receptor for virus entry and also services as the target of virus-neutralizing antibodies, making it an attractive and leading viral antigen for vaccine development. No vaccine against any human coronavirus is available to date. In learning from the experience of developing Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV vaccine candidates in preclinical and clinical trials, the most promising strategies for SARS-CoV-2 vaccines should employ viral-vector platforms, properly adjuvanted recombinant protein or DNA/mRNA encoding an engineered sequence of trimeric S protein in pre-fusion conformation.
最近由严重急性呼吸系统综合症冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）爆发，被世界卫生组织（WHO）定性为可控制的全球大流行疾病。刺突（S）糖蛋白介导病毒进入宿主细胞时与血管紧张素转换酶 2（ACE2）受体的结合，也是病毒中和抗体的靶标，使其成为疫苗开发的有吸引力和领先的病毒抗原。迄今为止，尚无针对任何人类冠状病毒的疫苗。在从开发中东呼吸综合征冠状病毒（MERS-CoV）和 SARS-CoV 疫苗候选物的临床前和临床试验中吸取经验教训的基础上，SARS-CoV-2 疫苗最有前途的策略应该采用病毒载体平台、适当佐剂的重组蛋白或 DNA/mRNA 编码三聚体 S 蛋白的预融合构象的工程序列。
